Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report

Immune checkpoint inhibitors (ICIs) represent an important advance in the adjuvant treatment of patients with high-risk melanoma. Although the safety profile of anti-programmed cell death protein-1 (PD-1) is fairly acceptable, different immune-related adverse events (irAEs) are described. Herein we...

Descripción completa

Detalles Bibliográficos
Autores principales: d’Apolito, Maria, Spagnuolo, Rocco, Siciliano, Maria Anna, Barbieri, Vito, Cosco, Cristina, Fiorillo, Lucia, Cuomo, Onofrio, Zuccalà, Valeria, Correale, Pierpaolo, Pensabene, Licia, Rossi, Marco, Doldo, Patrizia, Tassone, Pierfrancesco, Tagliaferri, Pierosandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8772353/
https://www.ncbi.nlm.nih.gov/pubmed/35070249
http://dx.doi.org/10.1177/20406223211063024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8772353/
https://www.ncbi.nlm.nih.gov/pubmed/35070249
http://dx.doi.org/10.1177/20406223211063024

Ejemplares similares